secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0000950170-25-042644
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon Q4 net loss $44.6M; cash runway extended; tegoprubart used in pig kidney transplant
--------------------------------------------------------------------------------

- Q4 2024 net loss $44.6M ($0.64/shr) vs $30.1M ($1.00/shr) in Q4 2023; includes non-cash warrant loss $20.9M.
- FY 2024 net loss $36.2M vs $116.5M in 2023; excluding warrant changes, net loss $67.1M vs $40.3M.
- Cash $140.2M at Dec 31, 2024; $85M oversubscribed offering extends runway to end of 2026.
- Tegoprubart used in second genetically modified pig kidney transplant (Jan 25, 2025) at Mass General; patient off dialysis.
- Positive initial data on islet transplant recipients; insulin independence without tacrolimus; topline Ph2 BESTOW due Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000095017025042644/0000950170-25-042644-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000095017025042644/eldn-20250320.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-042644

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer